Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. (Q45289817)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2005

Language	Label	Description	Also known as
English	Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.	scientific article published in March 2005

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

T Vassiliadis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

N Nikolaidis

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

O Giouleme

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

K Tziomalos

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

N Grammatikos

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

K Patsiaoura

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

D Gkisakis

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

K Theodoropoulos

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

P Katsinelos

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

E Orfanou-Koumerkeridou

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

N Eugenidis

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

531-537

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15740536%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02388.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45289817&oldid=1584895236"